April 15, 2013: BioAegis Therapeutics Engages FujiFilm Diosynth Biotechnlogies to Manufacture Clinical-Grade Supply of Recombinant Human Plasma Gelsolin

Supplies to be Used in Forthcoming Human Trials

BOSTON MASSACHUSSETTS and MORRISTOWN, NEW JERSEY–(BIOAEGIS THERAPEUTICS – April 15, 2013) BioAegis Therapeutics announced today that it has engaged the Billingham, UK group of Fujifilm Diosynth—a first-tier
contract biologics manufacturer, to manufacture clinical-grade supplies of recombinant human plasma gelsolin, the body’s 4th most abundant plasma protein that becomes depleted in myriad disease condtions and injuries. . BioAegis is preparing for human clinical trials to demonstrate that repletion of plasma gelsolin can prevent prevent excess inflammation that results in organ damage while boosting the body’s response to pathogens. FujiFilm Diosynth Biotechnologies is a tier-1 cGMP Contract Development and Manufacturing Organization (CDMO) that supports the development and production of therapeutic candidates.